Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC increased its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 5.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,663 shares of the biotechnology company’s stock after acquiring an additional 2,000 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in Anavex Life Sciences were worth $405,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Anavex Life Sciences by 25.8% in the 4th quarter. SG Americas Securities LLC now owns 34,844 shares of the biotechnology company’s stock worth $374,000 after acquiring an additional 7,138 shares during the period. Prairiewood Capital LLC bought a new stake in shares of Anavex Life Sciences during the fourth quarter valued at approximately $223,000. Carnegie Investment Counsel boosted its position in shares of Anavex Life Sciences by 4.7% during the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after buying an additional 3,445 shares during the period. SeaCrest Wealth Management LLC bought a new position in Anavex Life Sciences in the 4th quarter worth approximately $164,000. Finally, Fiduciary Alliance LLC bought a new position in Anavex Life Sciences in the 4th quarter worth approximately $119,000. Institutional investors own 31.55% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on AVXL shares. HC Wainwright reiterated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday. D. Boral Capital reissued a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research note on Tuesday.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL opened at $9.70 on Thursday. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The stock has a fifty day moving average price of $9.98 and a two-hundred day moving average price of $7.51. The firm has a market cap of $822.72 million, a P/E ratio of -18.65 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, research analysts predict that Anavex Life Sciences Corp. will post -0.73 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.